Use of psilocybin (“mushrooms”) among US adults: 2015-2018
R. Andrew Yockey, Keith A. King
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (29)
- The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. 2018-11-01 · Expand citations
- Long-term follow-up of psilocybin-facilitated smoking cessation. 2017-01-01 · Expand citations
- Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. 2016-05-01 · Expand citations
- Psilocybin--summary of knowledge and new perspectives. 2014-03-01 · Expand citations
- Over 30 million psychedelic users in the United States. 2013-01-01 · Expand citations
- Psychedelics and mental health: a population study. 2013-01-01 · Expand citations
- Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. 2011-11-01 · Expand citations
- Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. 2006-11-01 · Expand citations
- The pharmacology of psilocybin. 2002-10-01 · Expand citations
- [Psychedelic experiences at the onset of productive episodes of endogenous psychoses]. 1994-03-01 · Expand citations
- OpenAlex W1943380254
- OpenAlex W1984233408
- OpenAlex W2045364871
- OpenAlex W2056774128
- OpenAlex W2065164655
- OpenAlex W2091746900
- OpenAlex W2109879177
- OpenAlex W2113099805
- OpenAlex W2121949652
- OpenAlex W2125568653
- OpenAlex W2159403151
- OpenAlex W2759938474
- OpenAlex W2909369915
- OpenAlex W2924715128
- OpenAlex W2996870046
- OpenAlex W377295446
- OpenAlex W4244442112
- OpenAlex W6646295030
- OpenAlex W6661757993
Cited by — these papers cite this paper (10)
- Cannabis and Psilocybin Co-use: Associations with Stress and Well-being 2026-10-13 · Expand citations
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development 2026-07-03 · Expand citations
- Psilocybin use in Puerto Rico: Patterns, motivations, and personality correlates from an online survey 2026-04-15 · Expand citations
- Exploring the first use of psychedelic macrodoses in Latin American adults: Sociodemographic profiles, consumption factors, and subjective experiences 2025-11-20 · Expand citations
- Change in occupational burnout measures in emergency medical service workers after a psychedelic experience induced by a single self-administered dose of psilocybin mushrooms 2024-09-09 · Expand citations
- Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports 2024-07-17 · Expand citations
- Quantification of psilocin in human whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS) 2024-03-01 · Expand citations
- Assessing Metro Vancouver Residents’ Knowledge and Opinions of Psilocybin 2023-10-12 · Expand citations
- Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy 2023-08-21 · Expand citations
- Safer Tripping: Serotonergic Psychedelics and Drug Checking. Submission and Detection Rates, Potential Harms, and Challenges for Drug Analysis 2021-07-26 · Expand citations